newswire, breaking biotechnology and pharma news

Friday, November 12, 2010


Point Roberts, WA –November 12, 2010 ( Newswire and -, a leader in sector research tools
for investors, features a Biotech /Pharma Sector Trading Snapshot featuring some of the
NASDAQ’s market performers for the week. In todays down markets, Spectrum Pharmaceuticals,
Inc and Jazz Pharmaceuticals, Inc are in the green.

Biotech /Pharma Sector Trading Snapshot: (as of time of release November 12th)

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) trading at $4.5899, up 0.1699 (3.84%)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.56
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) trading at $ 15.15, up 0.03 (0.20%)

Market Summary (at time of release)

Dow 11,172.60 -110.50 -0.98%
NASDAQ 2,515.66 -39.86 -1.56%
S&P 500 1,197.46 -16.08 -1.33%
10 Yr Bond (%) 2.7450% +0.0970
Oil 84.89 -2.92 -3.33%
Gold 1,387.70 -15.40 -1.10%

Biotech/Pharma Stocks Recent News;

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) News:

Investor Spotlight on BioSante Pharmaceuticals (NASDAQ: BPAX) Lead Product LibiGel® -
testosterone gel for the treatment of female sexual dysfunction
Market for LibiGel® has wide potential with predictions ranging from about $2.0 billion up
to $5 billion

Point Roberts, WA, LINCOLNSHIRE, Ill –November 9, 2010 ( Newswire,)
Investor ideas and its biotech portal present a company and product spotlight for BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) lead product LibiGel®.

Investors following biotech and pharmaceutical stocks can take an in-depth look at the current
status of LibiGel®, the clinical data, the market drivers and opportunities within the company
product brochure, recent news links and a recent Q&A with Mr. Stephen M. Simes, President and
CEO discussing LibiGel.

Highlights from the LibiGel Brochure:
Read the Full Brochure at:

LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who
suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-
blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal
women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-
approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through
the skin after applying a once-daily pea-sized topical application on the upper arm that delivers
testosterone to the bloodstream evenly over time.
Full Article:

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) News:

“Jazz Pharmaceuticals, Inc. announced today that Bruce Cozadd, the company's chairman and
chief executive officer, will present at the Lazard Capital Markets Healthcare Conference in New
York on Wednesday, November 17, 2010 at 9:00 a.m. Eastern Time.

A live webcast of the presentation may be accessed from the Investors section of the Jazz
Pharmaceuticals website at Please connect to the website prior
to the start of the conference call to ensure adequate time for any software downloads that may
be necessary to listen to the webcast.”

Full Article:

About Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ):
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and
commercializes innovative treatments for important, underserved markets in neurology and
psychiatry. For further information see

About Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI):
Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and
drug development operations with a primary focus in oncology. The Company’s strategy is
comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-
stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV
and ZEVALIN, and has two drugs, apaziquone and belinostat, in late stage development along
with a diversified pipeline of novel drug candidates. The Company has assembled an integrated
in-house scientific team, including clinical development, medical research, regulatory affairs,
biostatistics and data management, formulation development, and has established a commercial
infrastructure for the marketing of its drug products. The Company also leverages the expertise of
its worldwide partners to assist in the execution of its strategy. For more information, please visit
the Company’s website at

Research other biotech stocks at the Biotech stocks Directory: http://

About is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. is
known for its comprehensive stock directories in each sector and sector specific newswires

Sign up for free stock alerts on biotech stocks and other leading sectors!

More news - Visit the BPAX showcase profile at
Disclosure, Disclaimer/ BPAX is a paid advertising client on

About our Biotech investor portal: is a global meeting place for investors and industry following the
biotech and pharma sector, within Global visitors use the site daily to research
the latest news, articles, audio, research reports and our stock directories.

Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX

(three thousand per month BPAX) is a third party publisher of news and
research .Our sites do not make recommendations, but offer information portals to research
news, articles, stock lists and recent research. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment involves risk and possible
loss of principal. This site is currently compensated by featured companies, news submissions
and online advertising.
More info: Disclaimer: Disclosure:

C Van Zant: 800-665-0411 -
Source -

No comments:

Post a Comment